Ring finger protein 180 (RNF180)

Ring finger protein 180 (RNF180) is an E3 ubiquitin-protein ligase highly conserved within the RING finger family that acts as a tumor suppressor in multiple cancers, including gastric, lung, and breast cancer[1][2][3][4][5][6]. It functions primarily by promoting the polyubiquitination and degradation of key oncogenic proteins such as RhoC, RAD51, and C-myc, thereby inhibiting proliferation, invasion, metastasis, and energy metabolism of tumor cells[1][2][3]. Its expression levels have prognostic value, correlating with survival and progression in various cancers, and its modulation can affect sensitivity to targeted therapies such as EGFR inhibitors[2]. RNF180 is characterized by a RING domain which confers E3 ligase activity, placing it within the zinc finger family of E3 ubiquitin ligases[4][6]. Emerging research is exploring RNF180 as a therapeutic and prognostic target in oncology.

Other names

E3 ubiquitin-protein ligase RNF180RING finger protein 180RING-type E3 ubiquitin transferase RNF180RINESRNF180

Drugs targeting RNF180 primarily act by promoting or mimicking its E3 ubiquitin ligase activity, leading to degradation of target oncogenic proteins (e.g., RAD51, RhoC, C-myc). In the context of drug response (e.g., gefitinib), RNF180 increases sensitivity by degrading resistance proteins like RAD51.